Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

New Liposome Treatment for Community-acquired Pneumonia


The findings are of significance for pharmaceutical companies and the medical sector. This is in the context of a time of great struggle for antibiotic companies given the increase in instances of antibiotic resistant bacteria. What is of particular global concern is the acceleration of resistance. U.S. Centers for Disease Control and Prevention (CDC) data finds that many high-income countries are entering a “post-antibiotic era.”

Tim Sandle has written an article for BioPharma Trends on the subject of liposomes. Here is an extract:

"CAL02 is composed of liposomes engineered to entrap and neutralize a large panel of bacterial toxins, particularly those medically identified as causing severe complications. A liposome is a spherical vesicle having at least one lipid bilayer. In medical research, liposomes are considered one of the most versatile and promising drug-carrier devices."

To read the article, see: https://www.biopharmatrend.com/post/93-new-liposome-treatment-for-community-acquire-pneumonia/

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology


This post first appeared on Pharmaceutical Microbiology, please read the originial post: here

Share the post

New Liposome Treatment for Community-acquired Pneumonia

×

Subscribe to Pharmaceutical Microbiology

Get updates delivered right to your inbox!

Thank you for your subscription

×